Advertisement

Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias

Published:October 18, 2022DOI:https://doi.org/10.1016/j.cger.2022.07.008

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Geriatric Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Areosa S.A.
        • Sherriff F.
        • McShane R.
        Memantine for dementia.
        Cochrane Database Syst Rev. 2005; : CD003154
        • Graham L.
        AAFP and ACP release guideline on dementia treatment.
        Am Fam Physician. 2008; 77: 1173-1175
        • Birks J.
        Cholinesterase inhibitors for Alzheimer's disease.
        Cochrane Database Syst Rev. 2006; 2006: CD005593
        • Kobayashi H.
        • Ohnishi T.
        • Nakagawa R.
        • et al.
        The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis.
        Int J Geriatr Psychiatry. 2016; 31: 892-904
        • Bartus R.T.
        • Dean 3rd, R.L.
        • Beer B.
        • et al.
        The cholinergic hypothesis of geriatric memory dysfunction.
        Science. 1982; 217: 408-414
        • Adlimoghaddam A.
        • Neuendorff M.
        • Roy B.
        • et al.
        A review of clinical treatment considerations of donepezil in severe Alzheimer's disease.
        CNS Neurosci Ther. 2018; 24: 876-888
        • Xu H.
        • Garcia-Ptacek S.
        • Jönsson L.
        • et al.
        Long-term effects of cholinesterase inhibitors on cognitive decline and mortality.
        Neurology. 2021; 96: e2220-e2230
        • Attems Johannes
        • Jellinger Kurt
        The overlap between vascular disease and Alzheimer’s disease – lessons from pathology.
        BMC Med. 2014; 12: 206
        • Matsunaga S.
        • Kishi T.
        • Yasue I.
        • et al.
        Cholinesterase inhibitors for Lewy Body disorders: a meta-analysis.
        Int J Neuropsychopharmacol. 2015; 19: pyv086
        • Liu Mu-N
        • Chi-Ieong Lau
        • Ching-Po Lin
        Precision medicine for frontotemporal dementia.
        Front Psychiatry. 2019; 10https://doi.org/10.3389/fpsyt.2019.00075
        • Russ T.C.
        • Morling J.R.
        Cholinesterase inhibitors for mild cognitive impairment.
        Cochrane Database Syst Rev. 2012; 2012: CD009132
        • Lee J.-H.
        • Jeong S.-K.
        • Kim B.C.
        • et al.
        Donepezil across the spectrum of Alzheimer’s disease: dose optimization and clinical relevance.
        Acta Neurol Scand. 2015; 131: 259-267
      1. Pfizer Inc. Aricept (donepezil hydrochloride) [package insert]. U.S. Food and Drug Administration website.
        • Knopman D.S.
        Donepezil 23 mg: an empty suit.
        Neurol Clin Pract. 2012; 2: 352-355
        • Birks J.S.
        • Harvey R.J.
        Donepezil for dementia due to Alzheimer's disease.
        Cochrane Database Syst Rev. 2018; 6: CD001190
      2. Novartis. Exelon (rivastigmine tartrate) [package insert]. U.S. Food and Drug Administration website.
        • Birks J.S.
        • Grimley Evans J.
        Rivastigmine for Alzheimer's disease.
        Cochrane Database Syst Rev. 2015; : CD001191
        • Khoury R.
        • Rajamanickam J.
        • Grossberg G.T.
        An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmine.
        Ther Adv Drug Saf. 2018; 9: 171-178
        • Nordberg A.
        • Ballard C.
        • Bullock R.
        • et al.
        A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.
        Prim Care Companion CNS Disord. 2013; 15 (PCC.12r01412)
      3. Ortho-McNeil Neurologics. Razadyne (galantamine hydrobromide) [package insert]. U.S. Food and Drug Administration website.
        • Loy C.
        • Schneider L.
        Galantamine for Alzheimer's disease and mild cognitive impairment.
        Cochrane Database Syst Rev. 2006; 2006: CD001747
        • Kowal N.M.
        • Ahring P.K.
        • Liao V.W.Y.
        • et al.
        Galantamine is not a positive allosteric modulator of human α4β2 or α7 nicotinic acetylcholine receptors.
        Br J Pharmacol. 2018; 175: 2911-2925
        • Bakker C.
        • van der Aart J.
        • Hart E.P.
        • et al.
        Safety, pharmacokinetics, and pharmacodynamics of Gln-1062, a prodrug of galantamine.
        Alzheimers Dement (N Y). 2020; 6: e12093
      4. Forest Laboratories. Namenda (memantine HCl) [package insert]. U.S. Food and Drug Administration website.
        • McShane R.
        • Westby M.J.
        • Roberts E.
        • et al.
        Memantine for dementia.
        Cochrane Database Syst Rev. 2019; 3: CD003154
        • Dou K.X.
        • Tan M.S.
        • Tan C.C.
        • et al.
        Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials.
        Alzheimer's Res Ther. 2018; 10: 126
        • Hager K.
        • Baseman A.S.
        • Nye J.S.
        • et al.
        Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease.
        Neuropsychiatr Dis Treat. 2014; 10: 391-401
        • Wilcock G.
        • Möbius H.J.
        • Stöffler A.
        MMM 500 group. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).
        Int Clin Psychopharmacol. 2002; 17: 297-305
        • Orgogozo J.M.
        • Rigaud A.S.
        • Stöffler A.
        • et al.
        Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
        Stroke. 2002; 33: 1834-1839
        • Tan C.-C.
        • Yu J.-T.
        • Wang H.-F.
        • et al.
        Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis.
        J Alzhemiers Dis. 2014; 41: 615-631
        • Hansen R.A.
        • Gartlehner G.
        • Webb A.P.
        • et al.
        Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
        Clin Interv Aging. 2008; 3: 211-225
        • Guo J.
        • Wang Z.
        • Liu R.
        • et al.
        Memantine, donepezil, or combination therapy-What is the best therapy for Alzheimer's disease? A network meta-analysis.
        Brain Behav. 2020; 10: e01831
        • Campbell N.L.
        • Perkins A.J.
        • Gao S.
        • et al.
        Adherence and tolerability of Alzheimer's disease medications: a Pragmatic randomized trial.
        J Am Geriatr Soc. 2017; 65: 1497-1504
        • Matsunaga S.
        • Kishi T.
        • Nomura I.
        • et al.
        The efficacy and safety of memantine for the treatment of Alzheimer's disease.
        Expert Opin Drug Saf. 2018; 17: 1053-1061
        • Massoud F.
        • Desmarais J.E.
        • Gauthier S.
        Switching cholinesterase inhibitors in older adults with dementia.
        Int Psychogeriatr. 2011; 23: 372-378
        • Courtney C.
        • Farrell D.
        • Gray R.
        • et al.
        AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.
        Lancet. 2004; 363: 2105-2115
        • Howard R.
        • McShane R.
        • Lindesay J.
        • et al.
        Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer’s Disease (DOMINO-AD) trial: secondary and post hoc analyses.
        Lancet Neurol. 2015; 14: 1171-1181
        • Ismail Z.
        • Black S.E.
        • Camicioli R.
        • et al.
        Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia.
        Alzheimer's Dement. 2020; 16: 1182-1195
        • Ostrowitzki S.
        • Lasser R.A.
        • Dorflinger E.
        • et al.
        • SCarlet RoAD Investigators
        A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.
        Alzheimers Res Ther. 2017; 9: 95
        • Honig L.S.
        • Vellas B.
        • Woodward M.
        • et al.
        Trial of solanezumab for mild dementia due to Alzheimer's disease.
        N Engl J Med. 2018; 378: 321-330
        • Schneider L.
        A resurrection of aducanumab for Alzheimer's disease.
        Lancet Neurol. 2020; 19: 111-112
        • Prins N.D.
        • Scheltens P.
        Treating Alzheimer’s disease with monoclonal antibodies: current status and outlook for the future.
        Alz Res Ther. 2013; 5: 56
        • Baker J.
        • Schott J.M.
        AD and its comorbidities: an obstacle to develop a clinically efficient treatment?.
        Rev Neurol (Paris). 2022; (S0035-3787(22)00546-X)https://doi.org/10.1016/j.neurol.2022.03.001
        • Dyer O.
        Medicare’s decision not to fund Aduhelm changes the landscape for US pharma industry.
        BMJ. 2022; : 377https://doi.org/10.1136/bmj.o996
        • Decourt B.
        • Boumelhem F.
        • Pope 3rd, E.D.
        • et al.
        Critical Appraisal of amyloid Lowering agents in AD.
        Curr Neurol Neurosci Rep. 2021; 21: 39
        • Battle C.E.
        • Abdul-Rahim A.H.
        • Shenkin S.D.
        • et al.
        Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.
        Cochrane Database Syst Rev. 2021; 2: CD013306
        • Jin B.R.
        • Liu H.Y.
        Comparative efficacy and safety of cognitive enhancers for treating vascular cognitive impairment: systematic review and Bayesian network meta-analysis.
        Neural Regen Res. 2019; 14: 805-816
        • Smith E.E.
        • Barber P.
        • Field T.S.
        • et al.
        Canadian Consensus Conference on diagnosis and treatment of dementia (CCCDTD)5: guidelines for management of vascular cognitive impairment.
        Alzheimer's Dementia (New York, N Y.). 2020; 6: e12056
        • Ryan J.
        • Storey E.
        • Murray A.M.
        • et al.
        • ASPREE Investigator Group
        Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline.
        Neurology. 2020; 95: e320-e331
        • Bentham P.
        • Gray R.
        • Sellwood E.
        • et al.
        • AD2000 Collaborative Group
        Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial.
        Lancet Neurol. 2008; 7: 41-49
        • Thoonsen H.
        • Riichard E.
        • Bentham P.
        • et al.
        Aspirin in Alzheimer’s disease: increased risk of intracerebral hemorrhage: cause for concern?.
        Stroke. 2010; 41: 2690-2692
        • Meschia J.F.
        • Bushnell C.
        • Boden-Albala B.
        • et al.
        Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart association/American stroke association.
        Stroke. 2014; 45: 3754-3832
        • Sara Mondini
        • Ileana Madella
        • Andrea Zangrossi
        • et al.
        Cognitive reserve in dementia: Implications for cognitive training.
        Front Aging Neurosci. 2016; 8https://doi.org/10.3389/fnagi.2016.00084
        • Sanches C.
        • Stengel C.
        • Godard J.
        • et al.
        Past, present, and future of non-invasive brain stimulation approaches to Treat cognitive impairment in neurodegenerative diseases: time for a Comprehensive Critical review.
        Front Aging Neurosci. 2021; 12: 578339
        • Zelinski E.M.
        Far transfer in cognitive training of older adults.
        Restorative Neurol Neurosci. 2009; 27: 455-471
        • Bahar-Fuchs A.
        • Martyr A.
        • Goh A.M.Y.
        • et al.
        Cognitive training for people with mild to moderate dementia.
        Cochrane Database Syst Rev. 2019; (CD013069)
        • Hill N.T.
        • Mowszowski L.
        • Naismith S.L.
        • et al.
        Computerized cognitive training in older adults with mild cognitive impairment or dementia: a systematic review and meta-analysis.
        Am J Psychiatry. 2017; 174: 329-340
        • Phan S.V.
        • Osae S.
        • Morgan J.C.
        • et al.
        Neuropsychiatric symptoms in dementia: considerations for Pharmacotherapy in the USA.
        Drugs R D. 2019; 19: 93-115
        • Lyketsos C.G.
        • Lopez O.
        • Jones B.
        • et al.
        Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: Results from the cardiovascular health study.
        JAMA. 2002; 288: 1475-1483
        • Ismail Z.
        • McGirr A.
        • Gill S.
        • et al.
        Mild behavioral impairment and Subjective cognitive decline predict cognitive and functional decline.
        J Alzheimers Dis. 2021; 80: 459-469
        • Wancata J.
        • Windhaber J.
        • Krautgartner M.
        • et al.
        The consequences of non-cognitive symptoms of dementia in medical hospital departments.
        Int J Psychiatry Med. 2003; 33: 257-271
        • By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel
        American Geriatrics society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate medication Use in older adults.
        J Am Geriatr Soc. 2019; 67: 674-694
        • Schneider L.S.
        • Dagerman K.S.
        • Insel P.
        Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.
        JAMA. 2005; 294: 1934-1943
        • Cipriani G.
        • Lucetti C.
        • Nuti A.
        • et al.
        Wandering and dementia.
        Psychogeriatrics. 2014; 14: 135-142
        • Neubauer N.A.
        • Azad-Khaneghah P.
        • Miguel-Cruz A.
        • et al.
        What do we know about strategies to manage dementia-related wandering? A scoping review.
        Alzheimers Demen. 2018; 10: 615-628
        • Montero-Odasso M.
        • Verghese J.
        • Beauchet O.
        • et al.
        Gait and cognition: a complementary approach to understanding brain function and the risk of falling.
        J Am Geriatr Soc. 2012; 60: 2127-2136
        • Zhang W.
        • Low L.F.
        • Schwenk M.
        • et al.
        Review of Gait, cognition, and fall risks with Implications for fall prevention in older adults with dementia.
        Dement Geriatr Cogn Disord. 2019; 48: 17-29
        • Racey M.
        • Markle-Reid M.
        • Fitzpatrick-Lewis D.
        • et al.
        Fall prevention in community-dwelling adults with mild to moderate cognitive impairment: a systematic review and meta-analysis.
        BMC Geriatr. 2021; 21: 689
        • Morello R.T.
        • Soh S.E.
        • Behm K.
        • et al.
        Multifactorial falls prevention programmes for older adults presenting to the emergency department with a fall: systematic review and meta-analysis.
        Inj Prev. 2019; 25: 557-564
        • Lord S.R.
        • Close J.C.T.
        New horizons in falls prevention.
        Age Ageing. 2018; 47: 492-498
        • Lee L.
        • Molnar F.
        Driving and dementia: efficient approach to driving safety concerns in family practice.
        Can Fam Physician. 2017; 63: 27-31
        • Breen D.A.
        • Breen D.P.
        • Moore J.W.
        • et al.
        Driving and dementia.
        BMJ. 2007; 334: 1365-1369
        • Jacobs M.
        • Hart E.P.
        • Roos R.A.C.
        Driving with a neurodegenerative disorder: an overview of the current literature.
        J Neurol. 2017; 264: 1678-1696
        • Stamatelos P.
        • Economou A.
        • Stefanis L.
        • et al.
        Driving and Alzheimer's dementia or mild cognitive impairment: a systematic review of the existing guidelines emphasizing on the neurologist's role.
        Neurol Sci. 2021; 42: 4953-4963
        • Polzer E.R.
        • Nearing K.A.
        • Knoepke C.E.
        • et al.
        Firearm access and dementia: a qualitative study of reported behavioral disturbances and responses.
        J Am Geriatr Soc. 2022; 70: 439-448
        • Schwertner E.
        • Zelic R.
        • Secnik J.
        • et al.
        Biting the Bullet: firearm ownership in persons with dementia. A Registry-based Observational study.
        J Alzheimers Dis. 2021; 81: 179-188
        • Pinholt E.M.
        • Mitchell J.D.
        • Butler J.H.
        • et al.
        Is there a gun in the home?" Assessing the risks of gun ownership in older adults.
        J Am Geriatr Soc. 2014; 62: 1142-1146
        • Lee S.
        • Kirk A.
        • Kirk E.A.
        • et al.
        Factors associated with having a will, power of attorney, and advanced healthcare Directive in patients presenting to a Rural and Remote memory clinic.
        Can J Neurol Sci. 2019; 46: 319-330
        • Sellars M.
        • Chung O.
        • Nolte L.
        • et al.
        Perspectives of people with dementia and carers on advance care planning and end-of-life care: a systematic review and thematic synthesis of qualitative studies.
        Palliat Med. 2019; 33: 274-290
        • Manthorpe J.
        • Samsi K.
        Person-centered dementia care: current perspectives.
        Clin Interv Aging. 2016; 11: 1733-1740
        • Wendrich-van Dael A.
        • Bunn F.
        • Lynch J.
        • et al.
        Advance care planning for people living with dementia: an umbrella review of effectiveness and experiences.
        Int J Nurs Stud. 2020; 107: 103576
        • Cheng S.T.
        Dementia caregiver Burden: a research update and Critical analysis.
        Curr Psychiatry Rep. 2017; 19: 64
        • Chien L.Y.
        • Chu H.
        • Guo J.L.
        • et al.
        Caregiver support groups in patients with dementia: a meta-analysis.
        Int J Geriatr Psychiatry. 2011; 26: 1089-1098
        • Tretteteig S.
        • Vatne S.
        • Rokstad A.M.
        The influence of day care centres designed for people with dementia on family caregivers - a qualitative study.
        BMC Geriatr. 2017; 17: 5
        • Swan K.
        • Hopper M.
        • Wenke R.
        • et al.
        Speech-language pathologist interventions for Communication in moderate-severe dementia: a systematic review.
        Am J Speech Lang Pathol. 2018; 27: 836-852
        • Bennett S.
        • Laver K.
        • Voigt-Radloff S.
        • et al.
        Occupational therapy for people with dementia and their family carers provided at home: a systematic review and meta-analysis.
        BMJ Open. 2019; 9: e026308
        • Zhu X.C.
        • Yu Y.
        • Wang H.F.
        • et al.
        Physiotherapy intervention in Alzheimer's disease: systematic review and meta-analysis.
        J Alzheimers Dis. 2015; 44: 163-174